Cargando…
The Clinicalpathological Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis (VITT) Following ChAdOx1 (AstraZeneca AZD1222) Vaccination and Case Outcomes in Australia
Autores principales: | Tran, Huyen, Deng, Lucy, Wood, Nicholas, Chen, Vivien M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The American Society of Hematology. Published by Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9665282/ http://dx.doi.org/10.1182/blood-2022-168844 |
Ejemplares similares
-
Immunoglobulin A Vasculitis Following ChadOx1 nCoV-19/AZD1222 (AstraZeneca COVID-19 Vaccine) Vaccination
por: Seo, Hyun-Min, et al.
Publicado: (2023) -
Impact of Improper Storage of ChAdOx1-S (AstraZeneca) Vaccine on Its Efficacy and Safety
por: Mikołajczyk, Marek, et al.
Publicado: (2022) -
Immune thrombocytopenia following immunisation with Vaxzevria ChadOx1-S (AstraZeneca) vaccine, Victoria, Australia
por: Gordon, Sally F., et al.
Publicado: (2021) -
Primary adrenal insufficiency associated with Oxford-AstraZeneca ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia (VITT)
por: Varona, Jose F., et al.
Publicado: (2021) -
Psoriatic flare following Oxford-AstraZeneca ChAdOx1 COVID-19 and influenza vaccines
por: Teh, Natalie, et al.
Publicado: (2021)